Uncategorized

NexThera Files IND Application for Phase 1/2a Clinical Trial of NT-101 Eye Drop for Wet AMD

by Business Wire • 2024/07/16 • 0 Comments

BUSAN, South Korea--(BUSINESS WIRE)-- #BiopharmaceuticalCompany--NexThera submits an IND application for a clinical trial of NT-101 eye drop for Wet AMD, a leading cause of blindness in the elderly.

← EnChroma Announces Organizations Can Now Join International Color Blindness Awareness Month™ 2024

Resumen: Rávena, Ciudad de los Mosaicos, Patrimonio Mundial de la UNESCO, en colaboración con EnChroma y la Fondazione Paolina Brugnatelli, permite a los visitantes daltónicos redescubrir los colores de los mosaicos →

Post navigation